Rafael Holdings earnings release, June 11, 2026

Rafael Holdings, Inc. (RFL) · Form 8-K, Item 2.02 · Filed · SEC filing

Rafael Holdings Reports Third Quarter Fiscal

2026 Financial Results

NEWARK,

NJ – June 11, 2026 (GLOBE NEWSWIRE)

-

Rafael Holdings,

Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026.

“Yesterday, we were pleased to announce that we reached the completion of the last patient last visit of our pivotal Phase 3 TransportNPC™ trial, and we are grateful for the patients and families, advocacy organizations, and physicians who stood at the heart of this global effort.

Together, we have advanced the clinical understanding of NPC, as well as the lived experience of this devastating disease, as we work to deliver a potentially life changing treatment option for a community with significant unmet need,” said Joshua Fine, Chief Operating

Officer of Rafael Holdings. “We would also like to recognize the FDA for their long-term continued collaboration, and guidance in advancing this program.”

“Following our pre-NDA meeting with the FDA, we believe we have a clear and expedited path forward reflective of the urgency and unmet need in NPC and expect to submit our NDA in the second half of calendar 2026. NPC represents a high-unmet-need market, positioning Rafael Holdings to potentially unlock substantial, long-term value for our shareholders as we work toward transitioning Rafael Holdings into a commercial-stage biotechnology company,” said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael

Holdings.

Rafael Holdings, Inc. Third Quarter Fiscal Year 2026 Financial Results

As of April 30, 2026, we had cash and cash equivalents of $30.5 million.

For the three months ended April 30, 2026, we recorded a net loss attributable to Rafael Holdings of $4.2 million, or $0.08 per share, versus a net loss of $4.8 million, or $0.19 per share in the year ago period.

The year over year increase in net loss is largely attributable to the consolidation of Cyclo Therapeutic’s expenses following the acquisition of Cyclo in March 2025.

Research and development expenses were $4.9 million for the three months ended April 30, 2026, compared to $3.0 million in the year ago period. The year over year increase relates to the inclusion in the current year period of research and development spending at Cyclo following the March 2025 acquisition.

General and administrative expenses were $2.1 million for the three months ended April 30, 2026, compared to $3.2 million in the year ago period. The year over year decrease relates to a decrease in payroll, stock-based compensation expense and professional fees during the quarter ended April 30, 2026, offset by the inclusion of expenses at

Cyclo following the March 2025 acquisition.

Rafael Holdings, Inc. First Nine Months Fiscal Year 2026 Financial

Results

For the nine months ended April 30, 2026, we recorded a net loss attributable to Rafael Holdings of $20.5 million, or $0.40 per share, versus a net loss of $18.4 million, or $0.73 per share in the year ago period.

The year over year increase in net loss is attributable to the consolidation of Cyclo Therapeutic’s expenses following the acquisition of Cyclo in March 2025.

Research and development expenses were $16.9 million for the nine months ended April 30, 2026, compared to $5.3 million in the year ago period. The year over year increase relates to the inclusion in the current year period of spending at Cyclo following the March 2025 acquisition.

General and administrative expenses were $7.3 million for the nine months ended April 30, 2026, compared to $8.3 million in the year ago period. The decrease related to the inclusion of expenses at Cyclo following the March 2025 acquisition which was more than offset by reductions in payroll due to terminations and reduced stock-based compensation expense and professional fees.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is Trappsol®

Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (“NPC1”), a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company. Our lead candidate, Trappsol® Cyclo™, is the subject of an ongoing pivotal Phase 3 clinical trial.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended April 30, — (unaudited, in thousands, except share and per share data)

Three Months Ended April 30, – 2026Three Months Ended April 30, – 2025Nine Months Ended April 30, – 2026Nine Months Ended April 30, – 2025
REVENUEInfusion Technology$—42$—93
REVENUERental – Third Party6049173147
REVENUERental – Related Party30288984
REVENUEProduct revenue89243368243
REVENUETotal revenue179362630567
COSTS AND EXPENSESCost of Infusion Technology revenue31106
COSTS AND EXPENSESCost of Product revenue89299
COSTS AND EXPENSESGeneral and administrative2,1403,1707,2608,284
COSTS AND EXPENSESResearch and development4,8533,00316,8665,276
COSTS AND EXPENSESDepreciation and amortization4862153238
COSTS AND EXPENSESLoss on impairment of goodwill3,050
COSTS AND EXPENSESLoss from operations-6,870-5,913-23,678-16,396
COSTS AND EXPENSESInterest income2864721,0231,529
COSTS AND EXPENSESRealized gain on available-for-sale securities178
COSTS AND EXPENSESUnrealized (loss) on investment - Cyclo-1,393-5,144
COSTS AND EXPENSESUnrealized gain (loss) on convertible notes receivable, due from Cyclo383-719
COSTS AND EXPENSESInterest expense-6-165-327-490
COSTS AND EXPENSESGain on settlement of accounts payable and convertible notes payable3,7233,958
COSTS AND EXPENSESOther (loss) income, net-261545474
COSTS AND EXPENSESLoss before income taxes-2,893-6,462-18,970-20,968
COSTS AND EXPENSES(Provision for) benefit from income taxes-62,411-522,379
COSTS AND EXPENSESConsolidated net loss-2,899-4,051-19,022-18,589
COSTS AND EXPENSESNet income (loss) attributable to noncontrolling interests1,3277281,437-163
COSTS AND EXPENSESNet loss attributable to Rafael Holdings, Inc.-4,226-4,779-20,459-18,426
Loss per share attributable to common stockholdersBasic and diluted-0.08-0.19-0.4-0.73
Weighted average number of shares used in calculation of loss per shareBasic and diluted51,229,57625,238,50151,327,94325,131,655

Balance Sheet

April 30, 2026 — (in thousands, except share and per share data)

April 30, 2026 – (Unaudited)July 31, 2025
CURRENT ASSETSCash and cash equivalents30,49752,769
CURRENT ASSETSPrepaid clinical costs2,9191,045
CURRENT ASSETSOther receivables1,206
CURRENT ASSETSAccounts receivable, net of allowance for credit losses of $245 at April 30, 2026 and July 31, 2025294627
CURRENT ASSETSInventory276281
CURRENT ASSETSPrepaid expenses and other current assets872786
CURRENT ASSETSTotal current assets34,85856,714
CURRENT ASSETSProperty and equipment, net1,5241,596
CURRENT ASSETSNon-current prepaid clinical costs2441,399
CURRENT ASSETSConvertible notes receivable classified as available-for-sale2,1241,858
CURRENT ASSETSGoodwill19,93919,939
CURRENT ASSETSIntangible assets, net896994
CURRENT ASSETSIn-process research and development31,57531,575
CURRENT ASSETSInvestments750
CURRENT ASSETSOther assets8034
CURRENT ASSETSTOTAL ASSETS91,990114,109
CURRENT LIABILITIESAccounts payable7,0436,893
CURRENT LIABILITIESAccrued expenses2,7643,304
CURRENT LIABILITIESConvertible notes payable608614
CURRENT LIABILITIESDue to related parties, net535723
CURRENT LIABILITIESOther current liabilities7066
CURRENT LIABILITIESTotal current liabilities11,02011,600
CURRENT LIABILITIESAccrued expenses, noncurrent3,895
CURRENT LIABILITIESConvertible notes payable, noncurrent278
CURRENT LIABILITIESDeferred income tax liability138138
CURRENT LIABILITIESOther liabilities2727
CURRENT LIABILITIESTOTAL LIABILITIES11,18715,738
EQUITYClass A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of April 30, 2026 and July 31, 202588
EQUITYClass B common stock, $0.01 par value; 200,000,000 shares authorized, 51,206,648 issued and outstanding (excluding treasury shares of 101,487) as of April 30, 2026, and 50,789,697 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2025513508
EQUITYAdditional paid-in capital323,234322,161
EQUITYAccumulated deficit-252,722-232,263
EQUITYTreasury stock, at cost; 101,487 Class B shares as of April 30, 2026 and July 31, 2025-168-168
EQUITYAccumulated other comprehensive income related to unrealized income on available-for-sale securities624358
EQUITYAccumulated other comprehensive income related to foreign currency translation adjustment3,8973,787
EQUITYTotal equity attributable to Rafael Holdings, Inc.75,38694,391
EQUITYNoncontrolling interests5,4173,980
EQUITYTOTAL EQUITY80,80398,371
EQUITYTOTAL LIABILITIES AND EQUITY91,990114,109
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2025, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking... (truncated)elease. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contact:

Barbara Ryan

Barbara.ryan@rafaelholdings.com

(203) 274-2825

# # #²

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Rafael Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.